Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575

Modulation of tryptophan catabolism by regulatory T cells

Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020

Predictive Biomarkers in Cancer Immunotherapy: A Narrative Review Across Selected Solid Tumors

Puntambekar, M., Shery, N., Parokkaran, I. P., & Al-Hamas, M. (2025) · Cureus · doi:10.7759/cureus.88647 · Cited by 17

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Li, Y., Kang, Z., & Du, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70018 · Cited by 18

Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival

McGonagle, D., Bragazzi, N. L., Amital, H., & Watad, ‬. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102456 · Cited by 14

Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics

Ritu, R., Chandra, P., & Das, A. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01201-2 · Cited by 15

CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials

Drougkas, K., Karampinos, K. I., Karavolias, I., Gomatou, G., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., & Kotteas, E. A. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01054-2 · Cited by 15

Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives

Kanp, T., Dhuri, A., Bharath, M., Rode, K., Aalhate, M., Paul, P., Nair, R., & Singh, P. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01797 · Cited by 14

Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer

Morisada, M. V., Chamberlin, M. M., & Allen, C. T. (2018) · Head & Neck · doi:10.1002/hed.25101 · Cited by 14

Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?

Gardiner, R., Jahangeer, S. M., Forde, P. F., Ariffin, A. B., Bird, B., Soden, D. M., & Hinchion, J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9550-8 · Cited by 14

Update on Immunotherapy in Melanoma

Green, J. A., & Ariyan, C. E. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.12.010 · Cited by 15

Immunotherapy for oesophagogastric cancer

Davidson, M., & Chau, I. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1213233 · Cited by 14

Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Patel, P., Schutzer, S. E., & Pyrsopoulos, N. (2016) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v7.i3.242 · Cited by 16

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization

Rausch, J., Lopez, P. A., Bialojan, A., Denny, M., Langguth, P., Probst, H. C., Schild, H., & Radsak, M. P. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.06.013 · Cited by 14

Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis

Czaja, A. J. (2019) · Autoimmunity · doi:10.1080/08916934.2019.1641200 · Cited by 15

Neoadjuvant anti-tumor vaccination prior to surgery enhances survival

Fisher, S. A., Cleaver, A. L., Lakhiani, D. D., Khong, A., Connor, T., Wylie, B., Lesterhuis, W. J., Robinson, B. W. S., & Lake, R. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0245-7 · Cited by 14

CTLA‐4 inhibition facilitates follicular T and B cell interaction and the production of tumor‐specific antibodies

Jo, A., Jeong, D., Eum, H. H., Kim, N., Na, M., Kang, H., & Lee, H. (2023) · International Journal of Cancer · doi:10.1002/ijc.34438 · Cited by 14

Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies

Afshari, A. R., Sanati, M., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216955 · Cited by 14

Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?

Werner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 14

Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents

Sznol, M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.01.007 · Cited by 13

Dysregulation of peritoneal cavity B1a cells and murine primary biliary cholangitis

Yang, Y., Yang, W., Yao, Y., Ma, H.-D., Wang, Y., Li, L., Wu, Q., Gershwin, M. E., & Lian, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8853 · Cited by 13

Emerging therapeutic targets in esophageal adenocarcinoma

Gaur, P., Hunt, C. R., & Pandita, T. K. (2016) · Oncotarget · doi:10.18632/oncotarget.8777 · Cited by 13

Immunotherapy of advanced renal cell carcinoma: Current and future therapies

Gill, D. M., Hahn, A. W., Sonpavde, G., & Agarwal, N. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1212794 · Cited by 13

Molecular imaging biomarkers for cell-based immunotherapies

Haris, M., Bagga, P., Hariharan, H., McGettigan-Croce, B., Johnson, L. A., & Reddy, R. D. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1240-6 · Cited by 13

Activation and Exhaustion of Adaptive Immune Cells in Hepatitis B Infection

Gogoi, D., Borkakoty, B., Biswas, D., & Mahanta, J. (2015) · Viral Immunology · doi:10.1089/vim.2014.0115 · Cited by 13

Influence of human immune cells on cancer: studies at the University of Colorado

Bruno, T. C., French, J. D., Jordan, K. R., Ramirez, O., Sippel, T. R., Borges, V. F., Haugen, B. R., McCarter, M. D., Waziri, A. E., & Slansky, J. E. (2012) · Immunologic Research · doi:10.1007/s12026-012-8346-y · Cited by 13

The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma

Shaib, W. L., Nammour, J. P., Gill, H. S., Mody, M. D., & Saba, N. F. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110100 · Cited by 13

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy

Ohnuma, K., Hatano, R., Dang, N. H., & Morimoto, C. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1532559 · Cited by 13

CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses

Lewis, P., Poteet, E. C., Liu, D., Chen, C., LaBranche, C. C., Stanfield-Oakley, S., Montefiori, D. C., Ferrari, G., & Yao, Q. C. (2020) · Vaccines · doi:10.3390/vaccines8020284 · Cited by 13

Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC

Olaoba, O. T., Ligali, F. C., Alabi, Z. O., Akinyemi, A. O., & Ayinde, K. S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188483 · Cited by 13

Identification of CTLA-4-Positive Cells in the Human Tonsil

Tiemann, M., Atiakshin, D., Samoilova, V. E., & Buchwalow, I. (2021) · Cells · doi:10.3390/cells10051027 · Cited by 13

Suppression of Acute Graft-Versus-Host Response by TCDD Is Independent of the CTLA-4-IFN-γ-IDO pathway

Rohlman, D., Punj, S., Pennington, J. M., Bradford, S., & Kerkvliet, N. I. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft140 · Cited by 13

Correction: Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients

Fong, B., Jin, R. M., Wang, X., Safaee, M., Lisiero, D. N., Yang, I., Li, G., Liau, L. M., & Prins, R. M. (2012) · PLoS ONE · doi:10.1371/annotation/641c3e73-ee2c-4873-8896-1b3a2edc557b · Cited by 13

Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy

Zheng, S., Li, K.-Z., Feng, G., Wang, Y.-T., Jia-ning, W. A. N. G., Li, S., & Sun, Y.-D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02513-5 · Cited by 16

The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

Giacomo, A. M. D., Lahn, M., Eggermont, A. M. M., Fox, B. A., Ibrahim, R. A., Sharma, P., Allison, J. P., & Maio, M. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113501 · Cited by 13

Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target

Huo, M., Adeerjiang, Y., Abulitipu, A., Khan, U., Li, X.-X., Zhang, L., Tian, Y., Jiang, S., Xu, C., Chao, X.-Z., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1325575 · Cited by 12

Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma

Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade

Blanchard, L., Vina, E., Ljubetic, J., Meneur, C., Tarroux, D., Baez, M., Marino, A. E., Ortéga, N., Knorr, D. A., Ravetch, J. V., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102141 · Cited by 14

Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer

Johnson, S. B., & Yu, J. B. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0711-0 · Cited by 12

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Saad, M., Lee, S. J., Tan, A. C., Naqa, I. M. E., Hodi, F. S., Butterfield, L. H., LaFramboise, W. A., Storkus, W. J., Karunamurthy, A. D., Conejo-Garcia, J. R., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03450-3 · Cited by 12

Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy

Liu, W., Liu, C., Wang, H., Xu, L., Zhou, J., Li, S., Cheng, Y., Zhou, R., & Zhao, L. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.017 · Cited by 12

The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring

Vergati, M., Schlom, J., & Tsang, K. Y. (2011) · BioMed Research International · doi:10.1155/2011/182413 · Cited by 11

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice

Lalami, Y., & Awada, A. H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.001 · Cited by 13

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors

Lee, K., Kim, H., & Yoon, S. Y. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.060 · Cited by 12

New Approaches in Immunotherapy for the Treatment of Lung Cancer.

Quaratino, S., Forssmann, U., & Marschner, J.-P. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2014_428 · Cited by 17

Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy

Smilowitz, H. M., Sasso, D., Lee, E. W., Goh, G., Micca, P. L., & Dilmanian, F. A. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1423-9 · Cited by 12

The “Achilles' Heel” of Cancer and Its Implications for the Development of Novel Immunotherapeutic StrategiesPreprint

Joshi, K., Chain, B., Peggs, K. S., & Quezada, S. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027086 · Cited by 12

Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment—A Systematic Review of Current Evidence

Suartz, C. V., de Lima, R. D., de almeida, L. S., Liebl, B., Lopes, R. I., Reis, G. B. B., Sant’Anna, P. V. H., de Campos, V. D. F., Mota, J. M., Melão, B. V. L. A., et al. (2025) · European Urology Open Science · doi:10.1016/j.euros.2025.07.010 · Cited by 11

Breast cancer vaccination: Latest advances with an analytical focus on clinical trials

Vajari, M. K., Sanaei, M., Salari, S., Rezvani, A., Ravari, M. S., & Bashash, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110696 · Cited by 10

Immunotherapy in the Fight Against Bone Metastases: A Review of Recent Developments and Challenges

Peng, Z., Huang, W. P., Xiao, Z., Wang, J., Zhu, Y., Zhang, F., Lan, D., & He, F. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01256-7 · Cited by 16

Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers

Ghosh, S., O’Hara, M. P., Sinha, P., Mazumdar, T., Yapindi, L., Sastry, K. J., & Johnson, F. M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009316 · Cited by 11

New therapeutical strategies in the treatment of metastatic disease

Julia, F., Thomas, L., & Dalle, S. (2012) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2012.01487.x · Cited by 11

Antibody Therapies in Cancer

Wang, S., & Jia, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_1 · Cited by 11

Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player

Rosado, M. M., & Pioli, C. (2023) · Cancers · doi:10.3390/cancers15041093 · Cited by 11

Monoclonal Antibodies for Cancer Immunotherapy

Zarnani, A., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_16 · Cited by 11

Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression

Lima, H. R., Gasparoto, T. H., Malaspina, T. S. D. S., Marques, V. R., Vicente, M. J., Marcos, E. V. C., de Souza, F. C., Nogueira, M. R. S., Barreto, J. A., Garlet, G. P., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01724 · Cited by 11

Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy

Xie, F., Liang, R., Li, D., & Li, B. (2018) · Engineering · doi:10.1016/j.eng.2018.12.002 · Cited by 11

Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy

Udyavar, A. R., & Geiger, T. L. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0090-1 · Cited by 11

The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease

Tabeya, T., Yamamoto, M., Naishiro, Y., Ishigami, K., Shimizu, Y., Yajima, H., Suzuki, C., Seki, N., Takano, K., Himi, T., et al. (2014) · Modern Rheumatology · doi:10.3109/14397595.2014.882045 · Cited by 11

Adjuvanticity of a CTLA-4 3′ UTR complementary oligonucleotide for emulsion formulated recombinant subunit and inactivated vaccines

Li, X., Yang, L., Zhao, P., Yao, Y., Lu, F., Tu, L., Liu, J., Li, Z., Yu, Y., & Wang, L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.043 · Cited by 11

Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges

Pathania, A. S. (2024) · Cancers · doi:10.3390/cancers16122201 · Cited by 16

Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives

Luo, Y., Lu, J., Lei, Z., Zhu, H., Rao, D., Wang, T., Fu, C., Zhang, Z., Xia, L., & Huang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00621-w · Cited by 12

Master regulator: p53’s pivotal role in steering NK-cell tumor patrol

Wang, H., Chen, Q., Liu, Q., & Luo, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428653 · Cited by 11

Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review

Akabane, M., Chatzipanagiotou, O. P., Imaoka, Y., Schenk, A. D., & Pawlik, T. M. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s528709 · Cited by 10

An RNA Aptamer–Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients

Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0821 · Cited by 10

Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology

Babalola, B. A., Adebami, G. E., & Akinsuyi, O. (2021) · Global Journal of Cancer Therapy · doi:10.17352/2581-5407.000040 · Cited by 11

Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity

Guth, A., Hafeman, S., & DOW, S. W. (2012) · OncoImmunology · doi:10.4161/onci.21317 · Cited by 10

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials

Ge, Y., Zhang, H., Weygant, N., & Yao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640099 · Cited by 9

Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis

Xie, J., Peng, B., Xiao, Y., Chen, X., Zhang, X., Chen, D., Song, L., Xu, M., Liao, W., & Zhang, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01024a · Cited by 10

“Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“

Li, X., & Song, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646292 · Cited by 12

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis

Williams, C., Kennedy, A., Robinson, M. A., Lloyd, C., Dovedi, S. J., & Sansom, D. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871802 · Cited by 9

CTLA-4: Checkpoints beyond the membrane

Buchan, S. L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.002 · Cited by 9

Tumor immune therapy: Lessons from infection and implications for cancer – Can IL‐7 help overcome immune inhibitory networks?

Pellegrini, M., & Mak, T. W. (2010) · European Journal of Immunology · doi:10.1002/eji.201040603 · Cited by 9

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies

Quetglas, J. I., John, L. B., Kershaw, M. H., Álvarez‐Vallina, L., Melero, I., Darcy, P. K., & Smerdou, C. (2012) · OncoImmunology · doi:10.4161/onci.21679 · Cited by 9

The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment

Afshari, F., Soleymanjahi, S., Keshavarz‐Fathi, M., Roviello, G., & Rezaei, N. (2019) · Immunotherapy · doi:10.2217/imt-2018-0093 · Cited by 9

Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database

Cutroneo, P. M., Isgrò, V., Ientile, V., Santarpía, M., Ferlazzo, G., Fontana, A., Carrega, P., Matarangolo, E., Barnaba, S., Spina, E., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14413 · Cited by 10

Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors

Zheng, L., Yang, X., Wei, Y., You, J., Li, H., Liao, J., & Cheng, Y. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110738 · Cited by 9

Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future

Li, L., Liu, H.-T., Teng, Y., Deng, Z., Zhang, G.-L., Su, J., Ma, L., & Zhong, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2151891 · Cited by 9

Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer

Patel, S. P., Osada, T., Osada, K., Hurwitz, H. I., Lyerly, H. K., & Morse, M. A. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0184-3 · Cited by 9

Immunotherapy in genitourinary malignancies

Wattenberg, M. M., Fong, L. H., Madan, R. A., & Gulley, J. L. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000331 · Cited by 9

A Case Report of Metastatic Gastric Cancer Treated with Pembrolizumab during Pregnancy

Piemonti, L., Vettor, L., & Contro, E. (2024) · Fetal Diagnosis and Therapy · doi:10.1159/000540000 · Cited by 8

Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development

Navarrete, M., Costoya, C., Gálvez‐Cancino, F., Peggs, K. S., Marabelle, A., & Quezada, S. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-123559 · Cited by 8

Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy

Zhang, Y., Chen, X., Hu, B., Zou, B., & Xu, Y. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2374230 · Cited by 8

Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells

Tsaknakis, B., Schaefer, I., Schwörer, H., Sahlmann, C., Thoms, K., Blaschke, M., Ramadori, G. P., & Cameron, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0813-3 · Cited by 8

Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer

Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V. P., Gul, A. R. Z., Shahab Uddin, M. S., Homsi, M. U. A., & Dermime, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96494 · Cited by 8

Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia

Taghiloo, S., & Asgarian‐Omran, H. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01129-5 · Cited by 8

How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy

Linch, S. N., & Redmond, W. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0135-z · Cited by 8

Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy

Abdkarimi, S., Soofiyani, S. R., Elham, G., Abdolahi, H. M., Safarzadeh, E., & Baradaran, B. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13268 · Cited by 9

Immune checkpoint inhibitor-related myocarditis in patients with lung cancer

Cao, W., Han, S., Zhang, P., Mi, L., Wang, Y., Nie, J., Dai, L., Hu, W., Zhang, J., Chen, X., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13997-1 · Cited by 7

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects

Wang, J., Feng, Y.-F., & Liu, J.-H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1629879 · Cited by 8

Unleashing the immune response against childhood solid cancers

Anderson, J. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26548 · Cited by 7

Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens

Bhardwaj, J. S., Paliwal, S., Singhvi, G., & Taliyan, R. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123089 · Cited by 7

From biomarkers to a clue of biology: a computation-aided perspective of immune gene expression profiles in human type 1 diabetes

Han, D., Cai, X., Wen, J., Kenyon, N. S., & Chen, Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00320 · Cited by 7

Anticancer Drugs in End‐Stage Kidney Disease Patients

Janus, N., & Launay‐Vacher, V. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12371 · Cited by 7

Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma

Bennani-Baiti, N., Thanarajasingam, G., & Ansell, S. A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1147350 · Cited by 7

The Role of the Immune System in Ovarian Cancer and Implications on Therapy

Menderes, G., Schwab, C. L., Black, J., & Santin, A. D. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1147957 · Cited by 7

Tumor-infiltrating regulatory T cell: A promising therapeutic target in tumor microenvironment

Huang, T., Li, F., Wang, Y., Gu, J., & Lü, L. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003450 · Cited by 7

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy

Hasan, N., Yang, D. S., Gibson, S., Khaleghi, B., Ziari, R., & Kalebasty, A. R. (2025) · Oncotarget · doi:10.18632/oncotarget.28723 · Cited by 6

CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer

Lin, A. C., Moscarelli, J. R., Zhu, Y.-L., Lin, Z. P., & Ratner, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-06812-1 · Cited by 7

Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma

Bell, R. B., Leidner, R. S., Feng, Z., Crittenden, M. R., Gough, M. J., & Fox, B. A. (2015) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2015.05.026 · Cited by 6

Helper Innate Lymphoid Cells—Unappreciated Players in Melanoma Therapy

Garofalo, C., Cerantonio, A., Muscoli, C., Mollace, V., Viglietto, G., Marco, C. D., & Cristiani, C. M. (2023) · Cancers · doi:10.3390/cancers15030933 · Cited by 6

Establishment and validation of a novel CD8+ T cell-associated prognostic signature for predicting clinical outcomes and immunotherapy response in hepatocellular carcinoma via integrating single-cell RNA-seq and bulk RNA-seq

Qu, C., Yan, X., Wei, Y., Tang, F., & Li, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01092-z · Cited by 6

CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy

Keilholz, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4fe · Cited by 32

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 448

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 53

Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity

Roddie, C. (2016) · UCL Discovery (University College London)